HF 2022: DELIVER Extends Benefits of Dapagliflozin to the Full Spectrum of Pts with HF

Подробнее о видео

Watch on Radcliffe Cardiology:

In this short interview, Dr Scott Solomon (Brigham And Women's Hospital & Harvard Medical School, Boston, MA, US) discusses the design and baseline of the DELIVER trial.
This trial was designed to evaluate the effects of the dapagliflozin on cardiovascular death, heart failure (HF) hospitalization, or urgent HF visits in patients with HF with mildly reduced and preserved left ventricular ejection fraction (LVEF) (NCT03619213).

Discussion Points:
1. DELIVER – Aims, Trial Design & Notable Features
2. Trial Population
3. Differences in General Population Compared to Other Trials in HFpEF
4. Sub-Groups of Note
5. Asian Participants
6. Primary Endpoint

Recorded at Heart Failure 2022, Madrid.

This content is intended for healthcare professionals only.

Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.